文献速递白血病

低甲基化药物联合维奈克拉治疗急性髓系白血病:临床试验数据更新与实用考量

Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
PubMed 文献 · Am J Hematol · 2018-12-13

低甲基化药物(HMA,地西他滨或5-阿扎胞苷)联合Bcl-2抑制剂维奈克拉(VEN)是急性髓系白血病(AML)治疗的重要进展,一线及复发设置中完全缓解率高,提示两药协同。近期数据显示一线VEN-HMA的CR+CRi率可能超过70%,且在多种遗传亚型中观察到活性,包括对常规化疗反应极差的亚型。本文总结现有数据并提供接受VEN-HMA治疗患者的管理实用指南,建议基于方案指南、临床试验数据及真实世界证据分析。

要点

  • 一线VEN-HMA的CR+CRi率可能超过70%。
  • VEN-HMA在多种遗传亚型AML中观察到活性,包括对常规化疗反应极差的亚型。
  • 尽管VEN近期才获FDA批准用于AML,因其显著疗效和良好毒性特征,超说明书使用日益增多。

核心结论

  • HMA联合VEN在AML一线及复发设置中产生高完全缓解率,提示两药协同。
  • 近期数据显示一线VEN-HMA的CR+CRi率可能超过70%。
  • 该活性在多种遗传亚型AML中观察到,包括对常规化疗反应极差的亚型。

研究设计与样本

  • 本文为综述,总结现有VEN-HMA联合治疗数据并提供管理实用指南。
  • 建议基于方案指南、已发表临床试验数据及真实世界证据分析。

主要发现

  • HMA(地西他滨或5-阿扎胞苷)与VEN联合在一线及复发设置中完全缓解率高。
  • 近期数据提示一线VEN-HMA的CR+CRi率可能超过70%。
  • 该活性在多种遗传亚型AML中观察到,包括对常规化疗反应极差的亚型。

临床怎么用

  • 作者提供接受VEN-HMA治疗患者管理的实用指南,基于方案指南、临床试验数据及真实世界证据分析。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

One of the most promising developments in therapy for acute myeloid leukemia (AML) in recent years has been the combination of hypomethylating agents (HMA, either decitabine or 5-azacytidine) with the Bcl-2 inhibitor venetoclax (VEN). Although both classes of drugs have single-agent activity in AML, the combination has resulted in high rates of complete remission (CR) both in the frontline and relapsed settings suggesting synergy between these two agents. Recent data have suggested that CR + CR with incomplete count recovery rate may exceed 70% for frontline VEN-HMA. Moreover, this activity has been observed across various genetic subtypes of AML including those known to have very poor response to conventional chemotherapy. Although VEN has only recently obtained FDA approval for treatment of AML, there has been increasing on and off-label use of this combination given its striking efficacy and excellent toxicity profile. In this article, we summarize the current available data on this combination and offer practical guidelines for management of patients receiving VEN-HMA. Our recommendations are based on protocol guidelines, published data from clinical trials as well as from analysis of real world evidence from patients treated with this combination.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mei M, Aldoss I, Marcucci G, et al. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use. Am J Hematol. 2018. PMID: 30499168. doi:10.1002/ajh.25369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。